NFKB1 and cancer: One of the main issues of EGFR-based therapies in cancer cells is constitutive activation of EGFR-mediated downstream oncogenic signaling (MAPK, PI3K/AKT, JAK/STAT, and AKT/NF-kB pathway) by EGFR mutation, which thereby leads to the development of treatment resistance36.